Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00059215 · ClinicalTrials.gov registry record · Phase 2
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
A Phase 2 study of Cardiovascular Diseases and Heart Diseases, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 905
- Enrollment target
- 2
- Study locations
NCT00059215: Completed Phase 2 study of Cardiovascular Diseases and Heart Diseases, sponsored by Eli Lilly and Company.
NCT00059215 is a Phase 2 study of Cardiovascular Diseases and Heart Diseases that has completed, run by Eli Lilly and Company. The registered enrollment target is 905 participants, below the 26,971-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00059215, a Phase 2 study of Cardiovascular Diseases and Heart Diseases, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 905 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a catheter (a long thin tube) that has a small balloon on the end. In many cases, patients who have this procedure receive a stent, a small wire spring that helps keep the vessel open.
Primary Outcome
Number of participants with non-coronary artery bypass graft (non-CABG) Thrombolysis In Myocardial Infarction (TIMI) Major or Minor bleeding. A major bleed was defined as an intracranial hemorrhage OR a clinically overt hemorrhage with a \>5 g/dL decrease in hemoglobin. A minor bleed was defined as a clinically overt hemorrhage with a hemoglobin decrease \>=3 g/dL and \<= 5 g/dL.
Conditions Studied
Interventions
- DRUG Clopidogrel
- DRUG Prasugrel (CS-747)
Study Locations (2)
Massachusetts
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Boston
British Columbia
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4599) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Victoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 905 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-01 |
| Phase | Phase 2 |
What the finished NCT00059215 record still lists
NCT00059215 is an interventional study that assigns participants to a tested intervention. The registered 905 participants enrollment target is mid-sized for trials with a published cap, below the 26,971-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.
NCT00059215 reports a single indexed study location in Massachusetts, British Columbia.
Frequently Asked Questions
What is clinical trial NCT00059215 about?
NCT00059215 is a clinical study titled "A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)". The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a cath...
What is the current status of trial NCT00059215?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 905 participants. The study started on 2003-04. Estimated completion is 2004-01.
What conditions does trial NCT00059215 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Heart Diseases.
What interventions are being tested in trial NCT00059215?
The interventions under investigation include: Clopidogrel (DRUG), Prasugrel (CS-747) (DRUG).
Who is sponsoring clinical trial NCT00059215?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00059215 being conducted?
This trial has 2 study locations across Massachusetts, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00059215's enrollment target sits among peer trials
905 61st of 300 higher than 240 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Omega-3D: Omega-3 for Diet-Driven Health Disparities
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Virtual Care Strategies to Improve Participation in Cardiac Rehabilitation Among Veterans
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT05769777 · 901 participants · Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia